economics

Yale-New Haven Health System Designates Tirofiban as the Primary Glycoprotein IIb/IIIa Inhibitor

04/26/2017

Given the therapeutic equivalence, we have saved approximately $125K in the past 12 months by switching to tirofiban just at Yale-New Haven Hospital. The savings system-wide are even higher.

Given the therapeutic...

04/26/2017

Cath Lab Digest

Your Path to Success: Expert Advice

How Does Your Cath Lab Stack Up?

02/07/2017

Gary Clifton ;

In this month’s article, we call on our colleagues at MedAxiom to share their findings from the 2016 Cath Lab Survey. The survey results demonstrate some very compelling findings that correlate closely to the observations seen in assessments...

In this month’s article, we call...

02/07/2017

Cath Lab Digest

Your Path to Success: Expert Advice

Cardiac Bundles — What Are the Implications?

01/10/2017

Terumo Business Edge

In my interview with Ryan Graver, President of MedAxiom Ventures, we discuss some of the challenges and opportunities that will be facing many cardiac programs, but also look to the future, and how embracing and possibly expanding the...

In my interview with Ryan...

01/10/2017

Cath Lab Digest

Attacking the Crux of the Health Care Cost Crisis

09/07/2015

James Montgomery , MPH;

The key factor driving waste within the delivery system is the slow adoption of new medical knowledge that could improve outcomes, and reduce risks and (importantly) costs. This is the front line in the battle defining our healthcare future.

The key factor driving waste...

09/07/2015

Cath Lab Digest

Cath Lab Management

Case Study: Cardiac Rhythm Management Purchasing

05/28/2015

John D. Carroll , MD, FACC, FSCAI;

This article will review some circumstances unique to the CRM market and will provide a case study of one facility’s successful approach to CRM contracting.

This article will review some...

05/28/2015

Cath Lab Digest